Pulmatrix Reports Q1 Loss, Reiterates Going Concern Warning Amidst Eos Merger Dependence
PULM is trading near its 52-week low of $1.16 (9.5% above the low).
Summary
Pulmatrix reported a Q1 2026 net loss of $1.172 million and issued a going concern warning, stating its future operations are highly dependent on the successful merger with Eos SENOLYTIX.
Key Events · Financing and Capital Events · PULM
-
Going Concern Warning Issued
Management explicitly states "substantial doubt about its ability to continue as a going concern" after one year from the financial statement issuance date without the successful closing of the Eos SENOLYTIX merger.
-
Low Cash Position and Merger Dependence
As of March 31, 2026, cash and cash equivalents were $3.3 million, plus $0.7 million in restricted cash. The company anticipates this cash is sufficient only through the anticipated closing of the proposed Eos merger, with dissolution and liquidation as a potential alternative if the merger fails.
-
Q1 2026 Financial Results
The company reported a net loss of $1.172 million for the three months ended March 31, 2026, compared to a net loss of $1.808 million for the same period in 2025. Net cash used in operating activities was $1.067 million.
-
Eos SENOLYTIX Merger Details Reaffirmed
The filing reiterates the definitive merger agreement with Eos SENOLYTIX, which will result in current Pulmatrix stockholders owning approximately 6% of the combined company on a fully-diluted basis.
Analysis · PULM · Life Sciences
Pulmatrix's Q1 2026 financial report explicitly states "substantial doubt about its ability to continue as a going concern" without the successful consummation of its proposed merger with Eos SENOLYTIX. The company's cash and cash equivalents stand at $3.3 million, with an additional $0.7 million in restricted cash, which management believes is only sufficient to fund operations through the anticipated closing of the merger. This filing provides the full financial context for the previously announced Eos merger and the $1.0 million private placement, underscoring the critical nature of the merger for the company's survival and the significant dilution for existing shareholders (6% pro forma ownership).
At the time of this filing, PULM was trading at $1.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $1.16 to $9.37. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.